Drugs / Aripiprazole
Aripiprazole
also known as
Abilify · OPC-14597 · Abilify Maintena · AOM · APZ · AOM 400 · aripiprazole once-monthly · Aripiprazole: Abilify · +23 more
Other / unclassified targets DRD2, HTR1A, HTR2A via activation / inhibition
Regulatory milestones approvals, filings & regulatory actions · 17 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ABILIFY ASIMTUFII | — | 2025-03-28 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | ABILIFY MAINTENA KIT | — | 2014-12-05 – 2017-07-27 | fda.gov ↗ |
| Label expansions (11) | US (FDA) | ABILIFY | — | 2003-08-28 – 2014-12-12 | fda.gov ↗ |
| Approved | EU (EMA) | Abilify | — | 2004-06-04 | europa.eu ↗ |
| Approved | US (FDA) | ABILIFY | — | 2002-11-15 | fda.gov ↗ |
Trials 242 · started per year
today
US approved 2002
EU approved 2004
1
4
5
9
27
25
18
13
18
13
12
9
16
9
9
4
6
10
10
6
3
3
4
3
3
2
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
Also used as a comparator or background therapy in 129 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT07215884 Comparator | Sep 2025 → Jun 2026 overdue | stutter disorder | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 1 | NCT05542264 Comparator | Nov 2022 → Feb 2024 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05402111 Comparator | Jun 2022 → Sep 2023 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02634463 Background | Nov 2015 → Nov 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01354353 Comparator | May 2011 → Mar 2012 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 1 | NCT01424449 Background | Jan → Jul 2010 | depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01556763 Background | Apr → Aug 2008 | schizoaffective disorder, schizophrenia | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00466310 Comparator | Feb 2007 → Jan 2009 | schizophrenia | Duke University | Completed | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT07714213 Comparator | Oct 2026 → May 2028 expected | long COVID-19, post-infectious syndrome | Christiana Franke | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07703956 Comparator | Jul 2026 → Oct 2027 expected | schizophrenia | Vigonvita Life Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07550387 Comparator | May 2024 → Jan 2026 | schizophrenia 1 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04539951 Comparator | Sep 2020 → Jun 2027 expected | obsessive-compulsive disorder | Shanghai Mental Health Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03557931 Background | Jul 2018 → Oct 2019 | schizophrenia | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01981811 Comparator | Mar → May 2014 | bipolar I disorder, schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02574741 Comparator | Jun 2012 → Dec 2019 | autism spectrum disorder | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT01490086 Comparator | Dec 2011 → Mar 2013 | schizoaffective disorder, schizophrenia | Reviva Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01323205 Background | May 2011 → Nov 2012 | schizophrenia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01052103 Background | Jan 2010 → Jun 2012 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 2 | NCT00905307 Comparator | Jul 2009 → Sep 2010 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00845026 Comparator | Mar 2009 → May 2010 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 2 | NCT00667875 Comparator | Apr 2008 → May 2011 | alcohol dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT00580125 Comparator | Nov 2007 → Sep 2008 | schizophrenia | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00509067 Background | Nov 2007 → Mar 2011 | schizophrenia | Georgetown University | Completed | No outcome recorded |
| Phase 2 | NCT00279409 Comparator | Jul 2006 → Feb 2008 | attention deficit-hyperactivity disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT03485417 Comparator | Jun 2019 → May 2024 | schizophrenia, substance abuse, substance dependence, substance-induced psychosis | The University of Hong Kong | Completed | No outcome recorded |
| Phase 2/3 | NCT01129674 Comparator | Jun 2010 → Oct 2012 | schizophrenia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2/3 | NCT00910780 Comparator | Nov 2009 | diabetes mellitus | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 335 trials | ||||||
| Phase 3 | NCT07153406 Comparator | Sep 2025 → Sep 2026 expected | depressive disorder | Andalusian Public Foundation for Health Research in Seville | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06799559 Comparator | May 2025 → Jul 2026 overdue | schizophrenia | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06589817 Comparator | Oct 2024 → Jun 2026 overdue | schizophrenia | Chengdu Kanghong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03874494 Comparator | Nov 2019 → Aug 2021 | schizophrenia | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT03198078 Comparator | Jun 2017 → Apr 2023 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02431702 Comparator | Jul 2015 → Nov 2019 | schizophrenia | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01421342 Comparator | Dec 2012 → Aug 2015 | major depressive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 3 | NCT01567527 Comparator | Aug 2012 → Apr 2016 | bipolar I disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01655706 Comparator | Apr 2012 → Jan 2017 | major depressive disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT01149655 Comparator | Jul 2011 → Nov 2013 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01328093 Comparator | Apr 2011 → Oct 2012 | schizophrenia | Denovo Biopharma LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01292057 Comparator | Feb 2011 → Dec 2015 | alcohol dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 3 | NCT01111552 Comparator | Jul 2010 → Sep 2011 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01104766 Comparator | Apr 2010 → Dec 2011 | schizophrenia | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01081769 Comparator | Feb 2010 → Feb 2013 | schizophrenia | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 3 | NCT01009047 Comparator | Dec 2009 → Jun 2012 | schizophrenia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00683852 Comparator | Sep 2008 → Sep 2009 | major depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00665366 Comparator | Jun 2008 → Oct 2011 | manic bipolar affective disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00338273 Comparator | Dec 2006 → Nov 2007 | bipolar I disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT00288353 Comparator | Jan 2006 → Dec 2008 | bipolar disorder, schizoaffective disorder, schizophrenia | Northwestern University | Terminated | No outcome recorded |
| Phase 3 | NCT00198107 Comparator | Sep 2005 → Sep 2011 | autism spectrum disorder | Indiana University | Completed | No outcome recorded |
| Phase 3 | NCT00110461 Comparator | Mar 2005 → Feb 2007 | bipolar disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00149734 Background | Jan 2005 → May 2010 | schizophrenia | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 3 | NCT00095758 Comparator | Sep 2004 → Dec 2006 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00095745 Comparator | Sep 2004 → Nov 2007 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00194077 Comparator | Aug 2004 → Jan 2011 | bipolar disorder | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00194012 Comparator | Aug 2004 → May 2012 | bipolar disorder | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00237913 Comparator | Jul 2004 → Aug 2005 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00102063 Comparator | Jul 2004 → Aug 2006 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00095823 Comparator | Jun 2004 → Aug 2006 | major depressive disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00094432 Comparator | Jun 2004 → Nov 2006 | bipolar I disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00080314 Comparator | Jan 2004 → Oct 2006 | bipolar disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00095719 Comparator | Dec 2003 → Mar 2005 | Alzheimer disease | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00177164 Comparator | Nov 2003 → Mar 2008 | bipolar I disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 3 | NCT00712686 Comparator | Jun 2000 → Dec 2003 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 457 trials | ||||||
| Phase 4 | NCT06969755 Comparator | Sep 2025 → Jul 2030 expected | schizophrenia | Northwell Health | Recruiting | No outcome recorded |
| Phase 4 | NCT07047651 Background | Jun 2025 → Dec 2027 expected | treatment-refractory schizophrenia | Dr. Stavroula Rakitzi | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06501339 Comparator | Aug 2024 → Oct 2025 overdue | treatment-refractory schizophrenia | All India Institute of Medical Sciences, Bhubaneswar | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05361993 Comparator | Jun → Dec 2024 | tic disorder | Children's Hospital of Fudan University | Withdrawn | No outcome recorded |
| Phase 4 | NCT05554627 Comparator | Oct 2023 | major depressive disorder | VA Office of Research and Development | Withdrawn | No outcome recorded |
| Phase 4 | NCT05741502 Comparator | Aug 2023 → Jan 2026 | schizophrenia | Ohio State University | Terminated | No outcome recorded |
| Phase 4 | NCT04903353 Comparator | Feb 2022 → Dec 2025 | autism spectrum disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05103410 Comparator | Nov 2021 → Jan 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04963257 Comparator | Jan 2020 → Dec 2023 | obsessive-compulsive disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT04203056 Comparator | Dec 2019 → Oct 2022 | schizoaffective depressive disorder, schizophrenia, schizophreniform disorder | University of California, Los Angeles | Terminated | No outcome recorded |
| Phase 4 | NCT03568500 Background | May 2018 → May 2019 | schizoaffective disorder, schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02146547 Comparator | Feb 2015 → Aug 2020 | schizophrenia | UMC Utrecht | Completed | No outcome recorded |
| Phase 4 | NCT03883204 Comparator | Jan 2015 → Dec 2020 | schizophrenia | Fundación Marques de Valdecilla | Unknown | No outcome recorded |
| Phase 4 | NCT02237417 Comparator | Sep 2014 → Nov 2018 | schizophrenia | University of Utah | Completed | No outcome recorded |
| Phase 4 | NCT02357849 Comparator | Jul 2014 → Apr 2022 | — | Northwell Health | Terminated | No outcome recorded |
| Phase 4 | NCT03090503 Comparator | Jun 2014 → Jun 2019 | schizophrenia | Fundación Marques de Valdecilla | Unknown | No outcome recorded |
| Phase 4 | NCT02532491 Comparator | May 2014 → May 2018 | schizophrenia | Fundación Marques de Valdecilla | Unknown | No outcome recorded |
| Phase 4 | NCT02091882 Background | Mar → Apr 2014 | — | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02040883 Background | Feb → Dec 2014 | schizophrenia | Qingyun Yin | Unknown | No outcome recorded |
| Phase 4 | NCT02339844 Comparator | Jan 2014 → Jan 2021 | schizophrenia | University of Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT01942187 Comparator | Aug 2013 → Dec 2015 | dysthymic disorder, major depressive disorder | New York State Psychiatric Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT01844700 Comparator | Jul 2013 → Apr 2014 | obesity due to melanocortin 4 receptor deficiency | Northwell Health | Terminated | No outcome recorded |
| Phase 4 | NCT01592201 Background | Jul 2012 → Jun 2013 | schizophrenia | Janssen Korea, Ltd., Korea | Terminated | No outcome recorded |
| Phase 4 | NCT01446328 Comparator | Oct 2011 → Dec 2017 | schizophrenia | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01495156 Background | Sep 2011 → Sep 2014 | bipolar I disorder | Northwell Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT01333072 Comparator | Jul 2011 → Aug 2015 | autism | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 4 | NCT01161277 Comparator | Aug 2010 → Jun 2011 | schizophrenia | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01193166 Comparator | Aug 2010 → Sep 2012 | schizophrenia | Ortho-McNeil Janssen Scientific Affairs, LLC | Withdrawn | No outcome recorded |
| Phase 4 | NCT01157351 Comparator | May 2010 → Dec 2013 | schizophrenia | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 4 | NCT00728312 Comparator | Aug 2009 → Apr 2010 | methamphetamine dependence | US Department of Veterans Affairs | Withdrawn | No outcome recorded |
| Phase 4 | NCT01047215 Comparator | Aug 2009 | bipolar disorder, schizophrenia | Taichung Veterans General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01305707 Comparator | Jul 2009 → Jul 2014 | major depressive disorder | Hospital Universitari de Bellvitge | Terminated | No outcome recorded |
| Phase 4 | NCT01714011 Comparator | May 2009 → Sep 2011 | schizophrenia | University of Malaya | Completed | No outcome recorded |
| Phase 4 | NCT00926835 Comparator | May 2009 → May 2015 | major depressive disorder | Ministry of Health & Welfare, Korea | Terminated | No outcome recorded |
| Phase 4 | NCT00806234 Comparator | Jan 2009 → Mar 2014 | psychotic disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT00895921 Comparator | Nov 2008 → Dec 2009 | diabetes mellitus | Veterans Medical Research Foundation | Completed | No outcome recorded |
| Phase 4 | NCT02526030 Comparator | Oct 2008 → Feb 2014 | schizophrenia | Fundación Marques de Valdecilla | Completed | No outcome recorded |
| Phase 4 | NCT00592683 Comparator | Dec 2007 → Apr 2010 | bipolar disorder | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00545467 Comparator | Aug 2007 → Jun 2009 | schizoaffective disorder, schizophrenia | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00325689 Comparator | Jul 2006 → Oct 2007 | schizoaffective disorder, schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00330863 Comparator | May 2006 → Jan 2011 | schizoaffective disorder, schizophrenia | Northwell Health | Completed | No outcome recorded |
| Phase 4 | NCT00205699 Comparator | Apr 2006 → Mar 2011 | attention deficit-hyperactivity disorder, bipolar disorder, oppositional defiant disorder, pervasive developmental disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00299702 Comparator | Feb 2006 → Jan 2009 | schizophrenia | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 4 | NCT00256997 Comparator | Jan 2006 → Apr 2009 | schizophrenia | Janssen-Ortho Inc., Canada | Terminated | No outcome recorded |
| Phase 4 | NCT00300846 Comparator | Dec 2005 → Jul 2007 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00351936 Comparator | Dec 2005 → Jul 2007 | schizophrenia | North Suffolk Mental Health Association | Completed | No outcome recorded |
| Phase 4 | NCT02305823 Comparator | Oct 2005 → Feb 2011 | schizophrenia | Fundación Marques de Valdecilla | Completed | No outcome recorded |
| Phase 4 | NCT02534363 Comparator | Oct 2005 → Jan 2011 | schizophrenia | Fundación Marques de Valdecilla | Completed | No outcome recorded |
| Phase 4 | NCT00305370 Background | Aug 2005 → Jan 2008 | attention deficit-hyperactivity disorder, bipolar disorder | Federal University of Rio Grande do Sul | Completed | No outcome recorded |
| Phase 4 | NCT00232687 Comparator | Jun 2005 → Apr 2007 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00712270 Comparator | Apr 2005 → Dec 2008 | schizophrenia | Kettering Health Network | Terminated | No outcome recorded |
| Phase 4 | NCT00654576 Comparator | Feb 2005 → Dec 2007 | schizophrenia | Central South University | Completed | No outcome recorded |
| Phase 4 | NCT00082199 Comparator | Apr 2004 → Aug 2005 | alcohol dependence | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00634348 Comparator | Apr 2004 → Mar 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00080327 Comparator | Nov 2003 → Sep 2004 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00685334 Comparator | Nov 2003 → Sep 2006 | anorexia nervosa | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00044655 Comparator | Jul 2001 → Mar 2009 | schizophrenia | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT06581302 Comparator | Sep 2024 → Dec 2025 overdue | psychotic disorder | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| — | NCT06467474 Background | Mar 2024 → Jun 2025 overdue | major depressive disorder | Ricardo Alberto Moreno, M.D., Ph.D. | Recruiting | No outcome recorded |
| — | NCT06372210 Background | Jun → Jul 2023 | bipolar I disorder, major depressive disorder, schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| — | NCT02955654 Comparator | Sep 2017 → Dec 2018 | obsessive-compulsive disorder | Shanghai Mental Health Center | Withdrawn | No outcome recorded |
| — | NCT02926976 Comparator | Nov 2016 → Sep 2019 | schizophrenia | Shanghai Mental Health Center | Unknown | No outcome recorded |
| — | NCT02137616 Comparator | Jun 2012 → Dec 2014 | psychotic disorder | Central South University | Unknown | No outcome recorded |
| — | NCT01338298 Comparator | Jan 2011 → Dec 2016 | hyperprolactinemia | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT00953745 Comparator | May 2009 → Jun 2012 | major depressive disorder | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT01154829 Comparator | Dec 2008 → May 2014 | schizophrenia | University of Copenhagen | Completed | No outcome recorded |
| — | NCT00288366 Comparator | Jan 2006 → Dec 2008 | bipolar disorder, schizoaffective disorder, schizophrenia | Northwestern University | Completed | No outcome recorded |
Press releases naming this drug 60 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-27 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Abilify Maintena 960mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia® otsuka.co.jp ↗ |
| 2023-04-28 | Otsuka Pharmaceutical Development & Commercialization, Inc. | FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII(aripiprazole), the First, Two-month, Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults® otsuka.co.jp ↗ |
| 2023-04-28 | Otsuka Pharmaceutical Development & Commercialization, Inc. | FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults otsuka-us.com ↗ |
| 2023-04-04 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as Aripiprazole 1-Month for Treatment of Schizophrenia and Bipolar I Disorder otsuka-us.com ↗ |
| 2022-09-13 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults otsuka-us.com ↗ |
| 2022-06-17 | Otsuka Pharmaceutical Development & Commercialization, Inc. | European Medicines Agency Commences Review of Aripiprazole2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole otsuka.co.jp ↗ |
| 2020-09-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka's ABILIFY MAINTENA approved for the additional indication of bipolar I disorder in Japan otsuka.co.jp ↗ |
| 2019-09-26 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Applies for the Additional Indication in Japan of Bipolar Disorder for ABILIFY MAINTENA for Suspended Release Injectable Suspension otsuka.co.jp ↗ |
| 2018-08-29 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Announces First Collaboration Agreement to Bring the ABILIFY MYCITE® System to the US Market otsuka-us.com ↗ |
| 2017-11-14 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Proteus Announce the First U.S. FDA Approval of a Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor) otsuka.co.jp ↗ |
| 2017-11-13 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka And Proteus® Announce The First U.S. FDA Approval of A Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor) otsuka-us.com ↗ |
| 2017-07-29 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MAINTENA® (aripiprazole) for Extended-Release Injectable Suspension Approved by U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder otsuka.co.jp ↗ |
| 2017-07-28 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Submits New Drug Application in Japan for Aripiprazole Sertraline Combination Tablets otsuka.co.jp ↗ |
| 2017-07-28 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MAINTENA® (Aripiprazole) for Extended-Release Injectable Suspension Approved by U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder otsuka-us.com ↗ |
| 2016-12-07 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck Present Data At ACNP Annual Meeting On Long-Acting Injectable Aripiprazole As A Potential Maintenance Treatment For Bipolar I Disorder otsuka-us.com ↗ |
| 2016-12-01 | Otsuka Pharmaceutical Development & Commercialization, Inc. | FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of Abilify Maintena® (aripiprazole) For The Treatment Of Bipolar I Disorder otsuka.co.jp ↗ |
| 2016-11-30 | Otsuka Pharmaceutical Development & Commercialization, Inc. | FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of ABILIFY MAINTENA® (aripiprazole) For The Treatment Of Bipolar I Disorder otsuka-us.com ↗ |
| 2016-11-18 | Otsuka Pharmaceutical Development & Commercialization, Inc. | New 1 mg Tablet Dosage of Antipsychotic ABILIFY Available in Japan otsuka.co.jp ↗ |
| 2016-09-28 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Antipsychotic ABILIFY Gains Approval in Japan for the Additional Indication of Irritability Associated with Pediatric Autism Spectrum Disorder otsuka.co.jp ↗ |
| 2016-03-02 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY for Extended Release Injectable Suspension, Used to treat Schizophrenia, Has Received Approval in Japan for Administration at Deltoid Muscle Site otsuka.co.jp ↗ |
| 2015-12-07 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism otsuka.co.jp ↗ |
| 2015-07-30 | Otsuka Pharmaceutical Development & Commercialization, Inc. | FDA Approves Deltoid Injection Site for Abilify Maintena® (aripiprazole) for extended-release injectable suspension in the Treatment of Schizophrenia otsuka-us.com ↗ |
| 2015-05-20 | Otsuka Pharmaceutical Development & Commercialization, Inc. | New Treatment Option in Japan for People Living With Schizophrenia - Abilify for Extended-release Injectable Suspension, for Intramuscular Use, Launched on May 25 otsuka.co.jp ↗ |
| 2015-04-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Launches Generic Abilify® Tablets in the United States tevapharm.com ↗ |
| 2015-03-30 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Pre-Filled Dual Chamber Syringe for Abilify Maintena® (Aripiprazole) Prolonged-Release Suspension for Injection, Used in the Treatment of Schizophrenia, Received Positive CHMP Opinion (Approval in EU) otsuka.co.jp ↗ |
| 2015-03-26 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY - ABILIFY for Extended-release Injectable Suspension, for Intramuscular Use - Indicated for Schizophrenia otsuka.co.jp ↗ |
| 2014-12-15 | Otsuka Pharmaceutical Development & Commercialization, Inc. | U.S. FDA Accepts for Review Supplemental New Drug Application for Deltoid Administration of Abilify Maintena® (aripiprazole) Extended-Release Injectable Suspension otsuka-us.com ↗ |
| 2014-12-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | U.S. FDA Approves The Labeling Update Of Abilify Maintena (Aripiprazole) For Extended-Release Injectable Suspension To Describe New Clinical Data For The Treatment Of Acutely Relapsed Adults With Schizophrenia ® otsuka.co.jp ↗ |
| 2014-11-03 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness to Paliperidone Palmitate Once-Monthly Injectable on Quality of Life Scale in Patients with Schizophrenia otsuka-us.com ↗ |
| 2014-09-29 | Otsuka Pharmaceutical Development & Commercialization, Inc. | U.S. FDA Approves Dual-Chamber Syringe for Abilify Maintena® (aripiprazole) Extended-Release Injectable Suspension for the Treatment of Schizophrenia otsuka-us.com ↗ |
| 2014-04-30 | Otsuka Pharmaceutical Development & Commercialization, Inc. | FDA Accepts For Review Otsuka Pharmaceutical And Lundbeck's Supplemental New Drug Application To Expand Abilify Maintena ® (Aripiprazole) Labeling otsuka-us.com ↗ |
| 2014-02-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka's Antipsychotic Aripiprazole Awarded the 60th Okochi Memorial Prize otsuka.co.jp ↗ |
| 2014-02-13 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck Announce Once-Monthly Abilify Maintena™ Approved in Canada for the Maintenance Treatment of Schizophrenia in Stabilized Adult Patients otsuka.co.jp ↗ |
| 2014-01-15 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical Submits Marketing Authorization Application in Japan for Abilify Once-Monthly Injectable Form for the Treatment of Schizophrenia otsuka.co.jp ↗ |
| 2013-11-21 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck's Once-Monthly Abilify Maintena® (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole otsuka.co.jp ↗ |
| 2013-09-20 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka And Lundbeck Receive Postive Chmp Opinion In Europe For Abilify Maintena, A Once-Monthly Injectable For Schizophrenia™ otsuka.co.jp ↗ |
| 2013-06-14 | Otsuka Pharmaceutical Development & Commercialization, Inc. | A New Choice of Therapy for the Treatment of Depression:ABILIFY® Granted Additional Approval as Adjunctive Therapy for the Treatment of Depression in Japan otsuka.co.jp ↗ |
| 2013-05-22 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Study Shows Effects of Treatment with ABILIFY MAINTENA™ (Aripiprazole) on Psychiatric Hospitalization Rates for Patients with Schizophrenia otsuka.co.jp ↗ |
| 2013-03-01 | Otsuka Pharmaceutical Development & Commercialization, Inc. | FDA Approves Once-Monthly ABILIFY MAINTENA™ (Aripiprazole) For Extended-Release Injectable Suspension for the Treatment of Schizophrenia otsuka.co.jp ↗ |
| 2013-02-06 | Otsuka Pharmaceutical Development & Commercialization, Inc. | The European Medicines Agency (EMA) Approves Aripiprazole (ABILIFY®) for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents. otsuka.co.jp ↗ |
| 2012-12-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck initiate the regulatory process for aripiprazole (once-monthly) depot formulation in Europe otsuka.co.jp ↗ |
| 2012-09-03 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY® ,The First Antipsychotic Agent in Japan Applying for Adjunctive Treatment in Major Depressive Disorder otsuka.co.jp ↗ |
| 2012-05-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | The Federal Circuit Decision Affirming the Validity of the Asserted Claims of Otsuka's Patent to ABILIFY® otsuka.co.jp ↗ |
| 2012-05-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Results from a Phase 3 Study of Once-monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting otsuka.co.jp ↗ |
| 2012-04-17 | Otsuka Pharmaceutical Development & Commercialization, Inc. | New Antipsychotic Agent "ABILIFY® OD Tablets" Pursues Agreeability for Patients, Enables easy Adherence otsuka.co.jp ↗ |
| 2012-01-18 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Antipsychotic Agent ABILIFY® Receives Regulatory Approvals for Additional Indication "Improvement of Manic Symptoms Associated with Bipolar Disorder" and for New Dosage Form "ABILIFY® OD Tablets" otsuka.co.jp ↗ |
| 2011-11-22 | Otsuka Pharmaceutical Development & Commercialization, Inc. | New Drug Application for Otsuka's Once-monthly Aripiprazole Depot Formulation for Maitenance Treatment of Adult Patients With Schizophrenia Accepted for Review by the U.S. Food and Drug Administration otsuka.co.jp ↗ |
| 2011-02-18 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY (aripiprazole) Approved for Maintenance Treatment of Bipolar I Disorder as an Adjunct to Either Lithium or ValproateData from 52-week maintenance trial showed superiority of adjunctive ABILIFY versus adjunctive placebo on primary study endpoint® otsuka.co.jp ↗ |
| 2011-01-24 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical Files for Additional Indication Regulatory Approval in Japan for ABILIFY, a Treatment for the Manic Symptoms Associated with Bipolar Disorder® otsuka.co.jp ↗ |
| 2010-12-16 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Defendants Appeal From Final Judgment in U.S. Abilify Patent Litigation® otsuka.co.jp ↗ |
| 2010-11-16 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Prevails in U.S. Abilify Patent Litigation® otsuka.co.jp ↗ |
| 2010-10-06 | Otsuka Pharmaceutical Development & Commercialization, Inc. | OTSUKA ANNOUNCES PHASE 3 ARIPIPRAZOLE INTRAMUSCULAR (IM) DEPOT TRIAL INTERIM ANALYSIS REVEALS EFFICACY CRITERIA MET otsuka.co.jp ↗ |
| 2009-11-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | U.S. Food and Drug Administration Approves ABILIFY (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)® otsuka.co.jp ↗ |
| 2009-04-06 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Bristol-Myers Squibb Extend U.S. Agreement for ABILIFY and Establish a Global Oncology Collaboration otsuka.co.jp ↗ |
| 2009-03-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Antipsychotic agent ABILIFY Oral Solution 0.1% to be Launched on April 10, 2009 in Japan® otsuka.co.jp ↗ |
| 2008-02-29 | Bristol-Myers Squibb | U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated with Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age) bms.com ↗ |
| 2007-11-09 | Otsuka Pharmaceutical Development & Commercialization, Inc. | U.S. FOOD AND DRUG ADMINISTRATION APPROVES ABILIFY (aripiprazole) AS THE FIRST MEDICATION FOR ADD-ON TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)® otsuka.co.jp ↗ |
| 2006-06-08 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Prix Galien awarded to Abilify (aripiprazole) for medical innovation® otsuka.co.jp ↗ |
| 2006-06-06 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Drug to treat schizophrenia with a new mechanism of action Antipsychotic agent "Abilify" Available in Japan from June 8 ® otsuka.co.jp ↗ |
| 2006-01-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka's Antipsychotic Abilify Is Approved in Japan, January 23, 2006® otsuka.co.jp ↗ |
Evidence & citations 39 cited values
Every value below carries the sentence it was read from. 382 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aripiprazole | “Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol...” NCT01323205 ↗368“Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗ “Work in a rodent relapse model has demonstrated that the atypical neuroleptic drug aripiprazole (Abilify), a partial agonist at dopamine D2 receptors, can block relapse to...” NCT00780702 ↗ “Subjects will be switched to Abilify Maintena (Aripiprazole) LAI monthly doses of 400mg, 300mg, 200mg or 160mg and have their sexual functioning reevaluated over a 3 month...” NCT02472652 ↗ “All the eligible participants will be randomly assigned to an oral atypical antipsychotic (risperidone, olanzapine, quetiapine, and where commercially available, aripiprazole...” NCT00256997 ↗ “Patients randomized to oral comparator arm will receive oral antipsychotics (haloperidol, paliperidone ER, risperidone, olanzapine, quetiapine or aripiprazole) as per...” NCT01081769 ↗ “Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\])” NCT01556763 ↗ “Oral Abilify (aripiprazole) is effective in the treatment of patients with BD when prescribed as an acute anti-manic agent and for the maintenance treatment of bipolar disorder.” NCT03408873 ↗ “TAU patients will continue receiving care as recommended by their physician which will include the use of Aripiprazole according to the approved labels.” NCT03881449 ↗ “United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)” NCT01052103 ↗ “Including Olanzapine, Risperidone, Paliperidone, Quetiapine, Aripiprazole, Ziprasidone, Lurasidone, Cariprazine, and all Typical antipsychotics” NCT05741502 ↗ “Therefore, this study aimed to investigate the effectiveness of adjuvant of aripiprazole (APZ) to MPH in patients with comorbid ADHD and DMDD.” NCT03358277 ↗ “Subjects eligible to participate in the study will receive IM saline and will use escitalopram 15 mg and aripiprazole 5 mg as randomized” NCT04234776 ↗ “An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.” NCT00149734 ↗ “Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder” NCT00177164 ↗ “Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response.” NCT02752542 ↗ “monotherapy with chlorpromazine, sulpiride, clozapine, risperidone, olanzapine, quetiapine, or aripiprazole.” PMID 21369751 ↗ Mar 2011 “Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type” NCT02168920 ↗ “Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg” NCT01016145 ↗ “Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)” NCT03376763 ↗ “AD: aripiprazole, bupropion, duloxetine, escitalopram, mirtazapine, sertraline, venlafaxine” NCT04747314 ↗ “Combination product of aripiprazole tablet embedded with sensor and wearable patch.” NCT03892889 ↗ “In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on.” NCT06467474 ↗ “Oral aripiprazole 5-30 mg daily, once or twice daily for the duration of the study” NCT07153406 ↗ “The initial dose of aripiprazole, the investigational product, is 2 mg once daily” NCT03423680 ↗ “The newest antipsychotic medication to be FDA approved is Aripiprazole (Abilify).” NCT00174876 ↗ “All patients will be treated with aripiprazole with a target dose of 10 mg/day” NCT01495156 ↗ “Aripiprazole (according to response, and tolerance)5-20mg” NCT01000402 ↗ “Aripiprazole IM Depot Formulation (OPC-14597 IMD)” NCT02220712 ↗ “Aripiprazole, 10～30mg/day, twice per day, 8 weeks” NCT02192723 ↗ “augmentation with antipsychotics (aripiprazole)” NCT06054321 ↗ “Risperdal® Consta® and Abilify® (Aripiprazole)” NCT00299702 ↗ “ASC-01 (aripiprazole/sertraline combination)” NCT02046564 ↗ “The initial dose of aripiprazole was 5mg/d” NCT04963257 ↗ “Oral aripiprazole-embedded IEM tablet.” NCT06372210 ↗ “- Aripiprazole 5-30 mg/d. N05AX12” NCT01305707 ↗ “Aripiprazole (Abilify)” NCT00567099 ↗ “Abilify(aripiprazole)” NCT00545675 ↗ “Drug: Aripiprazole” NCT00101569 ↗ “oral aripiprazole” NCT04203056 ↗ |
| Known as | Abilify | “Work in a rodent relapse model has demonstrated that the atypical neuroleptic drug aripiprazole (Abilify), a partial agonist at dopamine D2 receptors, can block relapse to...” NCT00780702 ↗16“Patients will be switched from their current antipsychotic medication to aripiprazole (Abilify) or ziprasidone (Geodon) (unless clinically contraindicated) for comparison with...” NCT00288366 ↗ “This is an investigator-initiated study whose primary aim is to determine the effectiveness of aripiprazole (Abilify®) in helping persons with symptoms of mania whose current...” NCT00221416 ↗ “Oral Abilify (aripiprazole) is effective in the treatment of patients with BD when prescribed as an acute anti-manic agent and for the maintenance treatment of bipolar disorder.” NCT03408873 ↗ “use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions” NCT00208169 ↗ “Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)” NCT00221962 ↗ “Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)” NCT00211302 ↗ “The newest antipsychotic medication to be FDA approved is Aripiprazole (Abilify).” NCT00174876 ↗ “receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM” NCT02237417 ↗ “Aripiprazole (Abilify®) IM Depot Injection” NCT01432444 ↗ “aripiprazole (Abilify)” NCT00288353 ↗ “aripiprazole (Abilify)” NCT00181779 ↗ “Abilify (aripiprazole)” NCT00541554 ↗ “Aripiprazole (Abilify)” NCT00567099 ↗ “Abilify(Aripiprazole)” NCT00545142 ↗ |
| Known as | Abilify asimtufii | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | Abilify Maintena | “Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole (Abilify).” NCT03408873 ↗ |
| Known as | Abilify maintena kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | ABILIFY MYCITE | “This is a 12 month, pragmatic trial designed to assess the differences in a digital medicine system (DMS)- ABILIFY MYCITE (Aripiprazole tablets with sensor)- measuring...” NCT03881449 ↗ |
| Known as | Abilify mycite kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | Ablify | “Olanzapine (Zyprexa), Quetiapine (Seroquel), Ziprasidone (Geodon), Aripiprazole (Ablify)” NCT00177164 ↗ |
| Known as | AOM | “OBJECTIVE: To evaluate aripiprazole once-monthly (AOM), a long-acting injectable suspension of aripiprazole, as acute treatment in patients with schizophrenia (DSM-IV-TR).” PMID 25188501 ↗ Nov 20142“The present study aimed to evaluate the efficacy and safety of aripiprazole once-monthly (AOM) compared to oral aripiprazole in treating acute schizophrenia.” PMID 34989824 ↗ Jan 2022 “Aripiprazole once-monthly (AOM), a long-acting injectable antipsychotic, is increasingly used in managing schizophrenia.” PMID 41034820 ↗ Oct 2025 |
| Known as | AOM 400 | “OBJECTIVE: To evaluate efficacy, safety, and tolerability of long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) as maintenance treatment for...” PMID 28146613 ↗ Mar 20171“The long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) was recently approved for maintenance treatment of bipolar I disorder (BP-I).” PMID 29886522 ↗ Jun 2018 |
| Known as | APZ | “OBJECTIVE: To examine the effectiveness and cognitive effects of aripiprazole (APZ) in children with a primary diagnosis of attention-deficit/hyperactivity disorder (ADHD).” PMID 18759644 ↗ Aug 20082“Therefore, this study aimed to investigate the effectiveness of adjuvant of aripiprazole (APZ) to MPH in patients with comorbid ADHD and DMDD.” NCT03358277 ↗ “Aripiprazole (APZ), effects dopamine and serotonin receptors with fewer limiting side effects seen with other atypical antipsychotics.” NCT00884884 ↗ |
| Known as | ARI | “Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)” NCT01742390 ↗ |
| Known as | ARI-OM | “The aim of this study was to evaluate the safety and tolerability of aripiprazole once-monthly (ARI-OM) for the maintenance treatment of schizophrenia.” PMID 23615694 ↗ Jul 2013 |
| Known as | Aripiprazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | Aripiprazole (extended-release injectable suspension): Abilify Maintena | “Aripiprazole (extended-release injectable suspension): Abilify Maintena®” NCT01795547 ↗ |
| Known as | Aripiprazole accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | Aripiprazole mylan pharma (previously aripiprazole pharmathen) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | aripiprazole once-monthly | “BACKGROUND: QUALIFY was a 28-week, randomized, open-label, head-to-head trial that assessed improvements across multiple measures in stable patients with schizophrenia with...” PMID 27927736 ↗ Jan 20171“Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.” PMID 34989824 ↗ Jan 2022 |
| Known as | Aripiprazole sandoz | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | Aripiprazole zentiva | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | Aripiprazole: Abilify | “Aripiprazole: Abilify®” NCT01795547 ↗1“Aripiprazole (Abilify)” NCT00567099 ↗ |
| Known as | Aripiprex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | AZP | “12- Week Open Label Treatment of Refractory Bipolar Depression (BD) With Combination of Depakote ER (DEP) and Aripiprazole (AZP)” NCT00223496 ↗ |
| Known as | BMS-337039 | “Aripiprazole (BMS-337039)” NCT01438060 ↗ |
| Known as | Lu AF41155 | “Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia” NCT01683058 ↗ |
| Known as | NSC-759266 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | OPC-14597 | “A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent...” NCT01122927 ↗7“A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of...” NCT00706654 ↗ “A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance...” NCT01149655 ↗ “A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients...” NCT01710709 ↗ “Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia” NCT01683058 ↗ “Intramuscular Formulation of Aripiprazole (OPC-14597)” NCT01567527 ↗ “OPC-14597 (Aripiprazole)” NCT00882362 ↗ “Aripiprazole, OPC-14597” NCT01909466 ↗ |
| Known as | OPC-14597 IMD | “Aripiprazole IM Depot Formulation (OPC-14597 IMD)” NCT02220712 ↗ |
| Known as | OPC-31 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | Opipza | ChEMBL registry synonym — accepted as the source's own label CHEMBL1112 ↗ |
| Known as | Rispridoen and Aripiprazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00352339 ↗ |
| Known as | Welbutrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02562430 ↗ |
| Action | Activate | “Serotonin 1a (5-HT1a) receptor partial agonist” CHEMBL1112 ↗2“Aripiprazole is a dopamine partial agonist” PMID 18765484 ↗ Sep 2008 “Dopamine D2 receptor partial agonist” CHEMBL1112 ↗ |
| Action | Inhibit | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL1112 ↗ |
| Modality | Other / unclassified | “Atypical antipsychotic” NCT01333072 ↗ |
| Route | Intramuscular | “Patients were randomly assigned to IM aripiprazole 1 mg, 5.25 mg, 9.75 mg, or 15 mg” PMID 17284138 ↗ Jan 2007 |
| Target | DRD2 | “Dopamine D2 receptor partial agonist” CHEMBL1112 ↗ |
| Target | HTR1A | “Serotonin 1a (5-HT1a) receptor partial agonist” CHEMBL1112 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL1112 ↗ |